Logo image of AZTA

AZENTA INC (AZTA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AZTA - US1143401024 - Common Stock

33.26 USD
-0.74 (-2.18%)
Last: 12/31/2025, 8:00:01 PM
33.26 USD
0 (0%)
After Hours: 12/31/2025, 8:00:01 PM
Fundamental Rating

4

AZTA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. AZTA has a great financial health rating, but its profitability evaluates not so good. AZTA has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

AZTA had positive earnings in the past year.
In the past year AZTA had a positive cash flow from operations.
In multiple years AZTA reported negative net income over the last 5 years.
AZTA had a positive operating cash flow in 4 of the past 5 years.
AZTA Yearly Net Income VS EBIT VS OCF VS FCFAZTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B 1.5B 2B

1.2 Ratios

Looking at the Return On Assets, with a value of -2.71%, AZTA is in line with its industry, outperforming 54.39% of the companies in the same industry.
AZTA has a Return On Equity (-3.23%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -2.71%
ROE -3.23%
ROIC N/A
ROA(3y)-3.69%
ROA(5y)10.48%
ROE(3y)-4.38%
ROE(5y)11.73%
ROIC(3y)N/A
ROIC(5y)N/A
AZTA Yearly ROA, ROE, ROICAZTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

1.3 Margins

With a Gross Margin value of 45.52%, AZTA perfoms like the industry average, outperforming 43.86% of the companies in the same industry.
In the last couple of years the Gross Margin of AZTA has remained more or less at the same level.
AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 45.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y0.54%
AZTA Yearly Profit, Operating, Gross MarginsAZTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 200 300

7

2. Health

2.1 Basic Checks

AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AZTA has more shares outstanding
Compared to 5 years ago, AZTA has less shares outstanding
AZTA has a better debt/assets ratio than last year.
AZTA Yearly Shares OutstandingAZTA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
AZTA Yearly Total Debt VS Total AssetsAZTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

An Altman-Z score of 4.24 indicates that AZTA is not in any danger for bankruptcy at the moment.
AZTA has a better Altman-Z score (4.24) than 77.19% of its industry peers.
The Debt to FCF ratio of AZTA is 0.04, which is an excellent value as it means it would take AZTA, only 0.04 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.04, AZTA belongs to the best of the industry, outperforming 92.98% of the companies in the same industry.
AZTA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
AZTA's Debt to Equity ratio of 0.00 is fine compared to the rest of the industry. AZTA outperforms 75.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.04
Altman-Z 4.24
ROIC/WACCN/A
WACC10.84%
AZTA Yearly LT Debt VS Equity VS FCFAZTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 2.98 indicates that AZTA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.98, AZTA is in line with its industry, outperforming 54.39% of the companies in the same industry.
AZTA has a Quick Ratio of 2.66. This indicates that AZTA is financially healthy and has no problem in meeting its short term obligations.
AZTA has a Quick ratio of 2.66. This is comparable to the rest of the industry: AZTA outperforms 56.14% of its industry peers.
Industry RankSector Rank
Current Ratio 2.98
Quick Ratio 2.66
AZTA Yearly Current Assets VS Current LiabilitesAZTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.27% over the past year.
Measured over the past years, AZTA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -16.04% on average per year.
Looking at the last year, AZTA shows a decrease in Revenue. The Revenue has decreased by -9.52% in the last year.
Measured over the past years, AZTA shows a quite strong growth in Revenue. The Revenue has been growing by 8.86% on average per year.
EPS 1Y (TTM)29.27%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%16.67%
Revenue 1Y (TTM)-9.52%
Revenue growth 3Y2.25%
Revenue growth 5Y8.86%
Sales Q2Q%-6.39%

3.2 Future

AZTA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.49% yearly.
The Revenue is expected to grow by 5.37% on average over the next years.
EPS Next Y50.72%
EPS Next 2Y39.62%
EPS Next 3Y34.08%
EPS Next 5Y27.49%
Revenue Next Year4.54%
Revenue Next 2Y4.91%
Revenue Next 3Y5.21%
Revenue Next 5Y5.37%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZTA Yearly Revenue VS EstimatesAZTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
AZTA Yearly EPS VS EstimatesAZTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2 2.5

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 62.75, which means the current valuation is very expensive for AZTA.
AZTA's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of AZTA to the average of the S&P500 Index (26.51), we can say AZTA is valued expensively.
Based on the Price/Forward Earnings ratio of 41.64, the valuation of AZTA can be described as expensive.
Based on the Price/Forward Earnings ratio, AZTA is valued a bit cheaper than the industry average as 61.40% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 23.13. AZTA is valued rather expensively when compared to this.
Industry RankSector Rank
PE 62.75
Fwd PE 41.64
AZTA Price Earnings VS Forward Price EarningsAZTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

AZTA's Enterprise Value to EBITDA ratio is in line with the industry average.
Based on the Price/Free Cash Flow ratio, AZTA is valued a bit cheaper than the industry average as 64.91% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 39.8
EV/EBITDA 28.45
AZTA Per share dataAZTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AZTA's earnings are expected to grow with 34.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.24
PEG (5Y)N/A
EPS Next 2Y39.62%
EPS Next 3Y34.08%

0

5. Dividend

5.1 Amount

No dividends for AZTA!.
Industry RankSector Rank
Dividend Yield 0%

AZENTA INC

NASDAQ:AZTA (12/31/2025, 8:00:01 PM)

After market: 33.26 0 (0%)

33.26

-0.74 (-2.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-21 2025-11-21/bmo
Earnings (Next)02-03 2026-02-03/amc
Inst Owners110.87%
Inst Owner ChangeN/A
Ins Owners1.07%
Ins Owner Change11.23%
Market Cap1.53B
Revenue(TTM)593.82M
Net Income(TTM)-55.76M
Analysts75.71
Price Target39.63 (19.15%)
Short Float %9.1%
Short Ratio6.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.43%
Min EPS beat(2)8.65%
Max EPS beat(2)36.22%
EPS beat(4)3
Avg EPS beat(4)13.04%
Min EPS beat(4)-29.97%
Max EPS beat(4)37.26%
EPS beat(8)7
Avg EPS beat(8)70.99%
EPS beat(12)10
Avg EPS beat(12)146.49%
EPS beat(16)14
Avg EPS beat(16)123.62%
Revenue beat(2)0
Avg Revenue beat(2)-2.8%
Min Revenue beat(2)-5.56%
Max Revenue beat(2)-0.05%
Revenue beat(4)0
Avg Revenue beat(4)-1.72%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)-0.05%
Revenue beat(8)2
Avg Revenue beat(8)-1.12%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)-0.95%
PT rev (1m)16.74%
PT rev (3m)23.64%
EPS NQ rev (1m)-13.92%
EPS NQ rev (3m)-23.25%
EPS NY rev (1m)1.2%
EPS NY rev (3m)1.35%
Revenue NQ rev (1m)-1.44%
Revenue NQ rev (3m)-3.88%
Revenue NY rev (1m)0.38%
Revenue NY rev (3m)0.1%
Valuation
Industry RankSector Rank
PE 62.75
Fwd PE 41.64
P/S 2.57
P/FCF 39.8
P/OCF 21.13
P/B 0.88
P/tB 1.65
EV/EBITDA 28.45
EPS(TTM)0.53
EY1.59%
EPS(NY)0.8
Fwd EY2.4%
FCF(TTM)0.84
FCFY2.51%
OCF(TTM)1.57
OCFY4.73%
SpS12.95
BVpS37.66
TBVpS20.12
PEG (NY)1.24
PEG (5Y)N/A
Graham Number21.19
Profitability
Industry RankSector Rank
ROA -2.71%
ROE -3.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 45.52%
FCFM 6.45%
ROA(3y)-3.69%
ROA(5y)10.48%
ROE(3y)-4.38%
ROE(5y)11.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y0.54%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.04
Debt/EBITDA 0.02
Cap/Depr 55.31%
Cap/Sales 5.7%
Interest Coverage N/A
Cash Conversion 182.57%
Profit Quality N/A
Current Ratio 2.98
Quick Ratio 2.66
Altman-Z 4.24
F-Score5
WACC10.84%
ROIC/WACCN/A
Cap/Depr(3y)47.53%
Cap/Depr(5y)73.52%
Cap/Sales(3y)6.46%
Cap/Sales(5y)8.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.27%
EPS 3Y0.64%
EPS 5Y-16.04%
EPS Q2Q%16.67%
EPS Next Y50.72%
EPS Next 2Y39.62%
EPS Next 3Y34.08%
EPS Next 5Y27.49%
Revenue 1Y (TTM)-9.52%
Revenue growth 3Y2.25%
Revenue growth 5Y8.86%
Sales Q2Q%-6.39%
Revenue Next Year4.54%
Revenue Next 2Y4.91%
Revenue Next 3Y5.21%
Revenue Next 5Y5.37%
EBIT growth 1Y70.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year516.37%
EBIT Next 3Y105.29%
EBIT Next 5YN/A
FCF growth 1Y210.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.11%
OCF growth 3YN/A
OCF growth 5Y13.75%

AZENTA INC / AZTA FAQ

Can you provide the ChartMill fundamental rating for AZENTA INC?

ChartMill assigns a fundamental rating of 4 / 10 to AZTA.


What is the valuation status of AZENTA INC (AZTA) stock?

ChartMill assigns a valuation rating of 4 / 10 to AZENTA INC (AZTA). This can be considered as Fairly Valued.


How profitable is AZENTA INC (AZTA) stock?

AZENTA INC (AZTA) has a profitability rating of 2 / 10.


Can you provide the financial health for AZTA stock?

The financial health rating of AZENTA INC (AZTA) is 7 / 10.


How sustainable is the dividend of AZENTA INC (AZTA) stock?

The dividend rating of AZENTA INC (AZTA) is 0 / 10 and the dividend payout ratio is 0%.